Aydin, Mesire;
de Leeuw, David C.;
Rutten, Caroline E.;
Visser, Otto J.;
Tang, Man Wai;
van Roessel, Cinthy;
Janssen, Jeroen J. W.;
Biemond, Bart J.;
van de Loosdrecht, Arjan A.;
Hazenberg, Mette D.;
Meijer, Ellen;
Nur, Erfan
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning
Beteiligte:
Aydin, Mesire;
de Leeuw, David C.;
Rutten, Caroline E.;
Visser, Otto J.;
Tang, Man Wai;
van Roessel, Cinthy;
Janssen, Jeroen J. W.;
Biemond, Bart J.;
van de Loosdrecht, Arjan A.;
Hazenberg, Mette D.;
Meijer, Ellen;
Nur, Erfan
Beschreibung:
<jats:title>Summary</jats:title><jats:p>Graft‐versus‐host disease (GvHD) is a serious complication of allogeneic haematopoietic stem cell transplantation (HSCT). Both anti‐thymocyte globulin (ATG) and post‐transplant cyclophosphamide (PTCy) are used as lymphocyte‐depleting strategies, yet a systematic comparison of transplantation outcomes between these two methods in matched unrelated donors (MUD) transplantations with non‐myeloablative conditioning (NMC) is lacking. Adult patients with haematological malignancies who had undergone MUD HSCT with NMC regimens between 2014 and 2021 at 2 centres in Amsterdam (ATG: <jats:italic>n</jats:italic> = 95, PTCy: <jats:italic>n</jats:italic> = 90), were included in this retrospective study. Patient characteristics were comparable between the groups. The cumulative incidence of acute GvHD grade II–IV was 48% in the ATG group compared to 21% in the PTCy group (<jats:italic>p</jats:italic> < 0.001). The 3‐year moderate/severe chronic GvHD was similar in both groups (<jats:italic>p</jats:italic> = 0.69). While the relapse rate was comparable between the groups (ATG 31% vs. PTCy 34%, <jats:italic>p</jats:italic> = 0.94), non‐relapse mortality tended to be higher in the ATG group (17% vs. 9%, <jats:italic>p</jats:italic> = 0.069). Overall survival was similar in both groups (<jats:italic>p</jats:italic> = 0.12). In conclusion, PTCy‐based regimens resulted in a significantly lower rate of acute GvHD than ATG‐containing regimens in MUD transplantations with NMC. Whether PTCy results in improved overall survival as compared to ATG needs to be elucidated in larger prospective studies.</jats:p>